Literature DB >> 7793326

Feline immunodeficiency virus as a model for development of molecular approaches to intervention strategies against lentivirus infections.

J H Elder1, T R Phillips.   

Abstract

Entities:  

Mesh：

Year:  1995        PMID： 7793326     DOI： 10.1016/s0065-3527(08)60062-7

Source DB:  PubMed          Journal:  Adv Virus Res        ISSN： 0065-3527            Impact factor:   9.937


× No keyword cloud information.
  22 in total

1.  Feline immunodeficiency virus-infected cat sera associated with the development of broad neutralization resistance in vivo drive similar reversions in vitro.

Authors:  S Giannecchini; D Matteucci; A Ferrari; M Pistello; M Bendinelli
Journal:  J Virol       Date:  2001-09       Impact factor: 5.103

2.  During readaptation in vivo, a tissue culture-adapted strain of feline immunodeficiency virus reverts to broad neutralization resistance at different times in individual hosts but through changes at the same position of the surface glycoprotein.

Authors:  M Bendinelli; M Pistello; D Del Mauro; G Cammarota; F Maggi; A Leonildi; S Giannecchini; C Bergamini; D Matteucci
Journal:  J Virol       Date:  2001-05       Impact factor: 5.103

3.  Evolution of two amino acid positions governing broad neutralization resistance in a strain of feline immunodeficiency virus over 7 years of persistence in cats.

Authors:  Mauro Pistello; Donatella Matteucci; Simone Giannecchini; Francesca Bonci; Olimpia Sichi; Silvano Presciuttini; Mauro Bendinelli
Journal:  Clin Diagn Lab Immunol       Date:  2003-11

4.  Studies of AIDS vaccination using an ex vivo feline immunodeficiency virus model: protection conferred by a fixed-cell vaccine against cell-free and cell-associated challenge differs in duration and is not easily boosted.

Authors:  D Matteucci; M Pistello; P Mazzetti; S Giannecchini; D Del Mauro; I Lonetti; L Zaccaro; C Pollera; S Specter; M Bendinelli
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

5.  Altered gag polyprotein cleavage specificity of feline immunodeficiency virus/human immunodeficiency virus mutant proteases as demonstrated in a cell-based expression system.

Authors:  Ying-Chuan Lin; Ashraf Brik; Aymeric de Parseval; Karen Tam; Bruce E Torbett; Chi-Huey Wong; John H Elder
Journal:  J Virol       Date:  2006-08       Impact factor: 5.103

6.  Alteration of substrate and inhibitor specificity of feline immunodeficiency virus protease.

Authors:  Y C Lin; Z Beck; T Lee; V D Le; G M Morris; A J Olson; C H Wong; J H Elder
Journal:  J Virol       Date:  2000-05       Impact factor: 5.103

7.  Kinetics of replication of a partially attenuated virus and of the challenge virus during a three-year intersubtype feline immunodeficiency virus superinfection experiment in cats.

Authors:  M Pistello; D Matteucci; G Cammarota; P Mazzetti; S Giannecchini; D Del Mauro; S Macchi; L Zaccaro; M Bendinelli
Journal:  J Virol       Date:  1999-02       Impact factor: 5.103

8.  AIDS vaccination studies using an ex vivo feline immunodeficiency virus model: failure to protect and possible enhancement of challenge infection by four cell-based vaccines prepared with autologous lymphoblasts.

Authors:  Simone Giannecchini; Patrizia Isola; Olimpia Sichi; Donatella Matteucci; Mauro Pistello; Lucia Zaccaro; Daniela Del Mauro; Mauro Bendinelli
Journal:  J Virol       Date:  2002-07       Impact factor: 5.103

Review 9.  Utilizing the FIV model to understand dendritic cell dysfunction and the potential role of dendritic cell immunization in HIV infection.

Authors:  Tracy L Lehman; Kevin P O'Halloran; Edward A Hoover; Paul R Avery
Journal:  Vet Immunol Immunopathol       Date:  2009-10-14       Impact factor: 2.046

10.  Structural basis for distinctions between substrate and inhibitor specificities for feline immunodeficiency virus and human immunodeficiency virus proteases.

Authors:  Ying-Chuan Lin; Zachary Beck; Garrett M Morris; Arthur J Olson; John H Elder
Journal:  J Virol       Date:  2003-06       Impact factor: 5.103
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.